UY39229A - Formas de dosificación oral sólidas de combinación de antagonistas de la hormona liberadora de gonadotropina - Google Patents

Formas de dosificación oral sólidas de combinación de antagonistas de la hormona liberadora de gonadotropina

Info

Publication number
UY39229A
UY39229A UY0001039229A UY39229A UY39229A UY 39229 A UY39229 A UY 39229A UY 0001039229 A UY0001039229 A UY 0001039229A UY 39229 A UY39229 A UY 39229A UY 39229 A UY39229 A UY 39229A
Authority
UY
Uruguay
Prior art keywords
dosage forms
oral dosage
solid oral
gonadotropin
combination
Prior art date
Application number
UY0001039229A
Other languages
English (en)
Inventor
David E Alonzo
Kathleen D Ullmer
Minli Xie
Original Assignee
Myovant Sciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myovant Sciences Gmbh filed Critical Myovant Sciences Gmbh
Publication of UY39229A publication Critical patent/UY39229A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)

Abstract

La presente descripción incluye formas de dosificación oral sólidas de combinación que tienen 40 mg de N-(4-(1-(2,6-difluorobencil)-5-((dimetilamino)metil)-3-(6-metoxi-3-piridazini -2,4-dioxo-1,2,3,4-tetrahidrotieno[2,3-d]pirimidin-6-il)fenil)-N'-metoxiurea, o una cantidad correspondiente de una sal farmacéuticamente aceptable de esta, y medicamentos de reemplazo hormonal. También se proporcionan procesos para elaborar y usar las formas de dosificación oral sólidas.
UY0001039229A 2020-05-29 2021-05-27 Formas de dosificación oral sólidas de combinación de antagonistas de la hormona liberadora de gonadotropina UY39229A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063032469P 2020-05-29 2020-05-29

Publications (1)

Publication Number Publication Date
UY39229A true UY39229A (es) 2021-12-31

Family

ID=76305879

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039229A UY39229A (es) 2020-05-29 2021-05-27 Formas de dosificación oral sólidas de combinación de antagonistas de la hormona liberadora de gonadotropina

Country Status (17)

Country Link
US (1) US20230165800A1 (es)
EP (1) EP4157227A1 (es)
JP (1) JP2023528014A (es)
KR (1) KR20230028732A (es)
CN (1) CN115666531A (es)
AR (1) AR122175A1 (es)
AU (1) AU2021278303A1 (es)
BR (1) BR112022023937A2 (es)
CA (1) CA3185151A1 (es)
CL (1) CL2022003338A1 (es)
CO (1) CO2022019160A2 (es)
EC (1) ECSP22098275A (es)
IL (1) IL298587A (es)
MX (1) MX2022015003A (es)
PE (1) PE20230859A1 (es)
UY (1) UY39229A (es)
WO (1) WO2021239917A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019006227A2 (pt) 2016-09-30 2019-06-18 Myovant Sciences Gmbh métodos de tratamento de leiomioma uterino e endometriose
CN115227648B (zh) * 2022-08-03 2023-09-29 南昌大学 一种瑞卢戈利固体自微乳及其制备方法和应用
CN115068421B (zh) * 2022-08-03 2023-08-04 南昌大学 一种瑞卢戈利纳米混悬液及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200506611B (en) 2003-01-29 2006-12-27 Takeda Pharmaceutical Thienopyrimidine compounds and use thereof
CN104703992B (zh) 2012-09-28 2019-03-05 武田药品工业株式会社 噻吩并嘧啶衍生物的制备方法
EP4233847A1 (en) 2015-02-26 2023-08-30 Takeda Pharmaceutical Company Limited A tablet comprising a methoxyurea derivative and mannitol particles
BR112019006227A2 (pt) 2016-09-30 2019-06-18 Myovant Sciences Gmbh métodos de tratamento de leiomioma uterino e endometriose
IL308528A (en) 2016-09-30 2024-01-01 Takeda Pharmaceuticals Co Prostate cancer treatment

Also Published As

Publication number Publication date
US20230165800A1 (en) 2023-06-01
BR112022023937A2 (pt) 2022-12-27
PE20230859A1 (es) 2023-05-30
KR20230028732A (ko) 2023-03-02
WO2021239917A1 (en) 2021-12-02
AU2021278303A1 (en) 2023-02-09
EP4157227A1 (en) 2023-04-05
CO2022019160A2 (es) 2023-03-27
JP2023528014A (ja) 2023-07-03
MX2022015003A (es) 2023-03-03
AR122175A1 (es) 2022-08-24
CA3185151A1 (en) 2021-12-02
CL2022003338A1 (es) 2023-06-30
CN115666531A (zh) 2023-01-31
ECSP22098275A (es) 2023-01-31
IL298587A (en) 2023-01-01

Similar Documents

Publication Publication Date Title
UY39229A (es) Formas de dosificación oral sólidas de combinación de antagonistas de la hormona liberadora de gonadotropina
AR109816A2 (es) Forma de dosificación farmacéutica para administración oral de un inhibidor de la familia bcl-2
ECSP045238A (es) Forma de dosis oral que contiene un inhibidor de pde 4 como un ingrediente activo y polivinilpirrolidona como excipiente
IT1271495B (it) Composizione farmaceutica contenente 3-2 (dimetilammino) etil-n-metil-1h-indol-5-metansolfonammide, relativo procedimento di preparazione e impiego della stessa nel trattamento di mammiferi
DOP2013000169A (es) Compuesto para uso en el tratamiento de la artritis
BRPI0519171A2 (pt) dispositivo de administraÇço de medicamento oftÁlmico
MXPA05004778A (es) Metodos de uso y composiciones que contienen compuestos inmunomoduladores para el tratamiento y manejo de enfermedades mieloproliferativas.
HK1089950A1 (en) Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form
AR045572A1 (es) Una combinacion que comprende n-(3-metoxi-5-metilpirazin-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil-3-sulfonamida y un analogo lhrh y/o un bifosfonato
CO5640087A2 (es) Composiciones de farmacos anti-inflamatorios no esteroideos descongestionantes y anti-histaminicos
AR054445A1 (es) Formulaciones de un inhibidor de src/abl
BR112019006228A2 (pt) tratamento de câncer de próstata
CY1113670T1 (el) Φαρμακευτικη συνθεση για τη θεραπεια της υπερδραστηριας ουροδοχου κυστης
EA200701681A1 (ru) Пероральная лекарственная форма, содержащая росиглитазон
EA202191061A1 (ru) фармацевтическая композиция для перорального введения, содержащая диметиламинA или его соль
AR052567A1 (es) Combinacion de bambuterol e inhibidor de integrina
DE60102590T2 (de) Darreichungsformen zur behandlung von oralen mykosen
AR056517A1 (es) Composiciones y metodos farmaceuticos utilizando temozolomida y un inhibidor de la proteina quinasa
NI200600270A (es) Una composición farmacéutica antimicobacteriana que comprende un farmaco antituberculosis
AR038858A1 (es) Combinacion
AR045330A1 (es) Forma de dosificacion oral, procedimiento para su preparacion y uso del compuesto 5-(4-(2-(n-metil-n- (2-piridil)amino)etoxi )bencil) tiazolidin-2,4-diona o una sal o solvato farmaceuticamente aceptable del mismo para prepararla
GT200000087A (es) Formas polimorfas de un citrato de azabiciclo(2.2.2) octan - 3 - amina y sus composiciones farmaceuticas.
AR109762A1 (es) Tratamiento de cáncer de próstata, formulación oral
AR062215A1 (es) Inhibidor de trombina activo por via oral
CR20110663A (es) Forma de dosificaciën farmacuutica para administraciën oral de un inhibidor de la familia bcl 2